Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Change in HbA1c (glycosylated hemoglobin) from Visit 1 to each protocol visit

Change in HbA1c from Visit 1 to each visit up to open-ended study termination

Time frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)

Change in body weight from Visit 1 to each protocol visit

Change in body weight (kg) from Visit 1 to each visit up to open-ended study termination

Time frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)

Change in fasting plasma glucose from Visit 1 to each protocol visit

Change in fasting plasma glucose from Visit 1 to each visit up to open-ended study termination

Time frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)

Change in lipids from Visit 1 to each protocol visit

Change in lipids from Visit 1 to each visit up to open-ended study termination

Time frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target)